Biocom Appoints New Board Chair and Adds to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Feb 26, 2019--Biocom, the association representing the California life science industry, today announced that Christophe Schilling, Ph.D., CEO and co-founder of Genomatica, assumed the chair position for the organization’s board of directors, while Richard Pascoe, chairman and CEO of Histogen, Inc., was appointed chair elect. Biocom also brought in new members to its board of directors and added individuals to its executive committee.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190226005891/en/
Biocom named Christophe Schilling, Ph.D., CEO and co-founder of Genomatica, the chair for the organization’s board of directors. (Photo: Business Wire)
“Dr. Schilling has brought valuable perspective and guidance during his eight years of service to the Biocom board, and I anticipate that during his term as chair, we will continue to grow and serve our California constituencies skillfully, through our focused public policy work, our innovative capital development programming, and our other extensive programs and services,” said Joseph Panetta, president and CEO of Biocom.
New board members were voted on in Biocom’s most recent board meeting and include:
- Bassil Dhaiyat, Ph.D., president and CEO, Xencor
- Rachel Haurwitz, Ph.D., president and CEO, Caribou Biosciences
- Andrew Lukowiak, Ph.D., CEO, Millennium Health
- Ted Jacobs, executive managing director, Cushman Wakefield
- Stanley Maloy, Ph.D., associate vice president for research & innovation and professor of biology, San Diego State University
- Tamera Weisser, Ph.D., J.D., partner, Jones Day
“The growth in our board signifies our strength as a state-wide organization representing the life sciences,” said Panetta. “We are continuing to add members across the state and to build distinct programming designed to address the unique needs of the geographic life science clusters that drive growth in our industry.”
In addition to bringing on new board members, Biocom added members to its executive committee. The new executive committee members voted on are:
- Peter Silvester, Thermo Fisher Scientific
- Lesley Stoltz, Ph.D., JLabs
- Jennifer Cayer, 3E Therapeutics
- Ranjeet Banerjee, BD
View Biocom’s full Board of Directors here.
Finally, Biocom announced that it has promoted Rick Fultz to the position of vice president, chief business officer, and Managing Director, Purchasing Group, with statewide responsibility for revenue-generating lines of business, in addition to marketing and business development.
Biocom is the largest, most experienced leader and advocate for California’s life science sector. We work on behalf of more than 1,100 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.
Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom operates core offices in Los Angeles and the San Francisco Bay Area, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190226005891/en/
CONTACT: Biocom Media Contact:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS MEDICAL DEVICES PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE
Copyright Business Wire 2019.
PUB: 02/26/2019 11:24 AM/DISC: 02/26/2019 11:24 AM